Harm reduction in the USA: the research perspective and an archive to David Purchase
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The history of harm reduction in the USA has led to the development of some of the most important methods for treating persons for drug use disorders, such as methadone and buprenorphine for opiate use disorder. However, there has been fierce political resistance to implementation and scale-up of harm reduction in the USA. This resistance is rooted in historical demonization of particular psychoactive drugs that were associated with stigmatized racial/ethnic groups.With the discovery of acquired immunodeficiency syndrome (AIDS) in 1981, harm reduction became important not only for treating substance use disorders, but for reducing transmission of blood-borne infection. However, within the context of the crack cocaine epidemic in the 1980s, it was very difficult to implement any programs that appeared to "condone" drug use.It was not until the late 1980s that syringe exchange programs began at the state and local level in the USA. With funding primarily from state and local governments and the support of the North American Syringe Exchange Network (NASEN), there are now approximately 200 programs for syringe exchange in the USA. Research has shown that these programs have been extremely effective in reducing human immunodeficiency virus (HIV) transmission among persons who inject drugs (PWID). The programs in the USA also offer many additional services for drug users, including condom distribution, referrals to substance abuse treatment, HIV, hepatitis C virus (HCV), hepatitis B virus (HBV) counseling and testing, overdose education and naloxone distribution to reverse for overdose.Currently, the USA is experiencing an opioid/heroin epidemic, with significant increases in overdose deaths among drug users. Much of this epidemic is occurring in suburban and rural of the country without harm reduction services. The current challenges for harm reduction and harm reduction research involve expansion of services to suburban and rural areas and implementation science on how to effectively and efficiently address HCV transmission and overdose. Most importantly, continued research efforts are needed to reduce the stigma of psychoactive drug use. While political opposition continues, harm reduction activists and researchers have developed a highly effective partnership based on a common core values.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Opioid Epidemic in the United States
Manchikanti, L. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/es9 · Cited by 1,180
Cited by
Clinical Management of Opioid Withdrawal.
Torres‐Lockhart, K. E., Lu, T. Y., Weimer, M. B., Stein, M. R., & Cunningham, C. O. (2022) · Addiction · doi:10.1111/add.15818 · Cited by 57
Brewerton, T. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1149433 · Cited by 46
The Ethical Defensibility of Harm Reduction and Eating Disorders
Bianchi, A., Stanley, K., & Sutandar, K. (2021) · The American Journal of Bioethics · doi:10.1080/15265161.2020.1863509 · Cited by 41
“…were primarily started and supported by public activists and were only later implemented by some mainstream governmental and healthcare systems (Des Jarlais 2017). rather to mitigate the possibility and severity of the potential harm(s).6 Harm reduction approaches are considered “inexpensive, easy…”
BackgroundWe know the streets:” race, place, and the politics of harm reduction
Owczarzak, J., Weicker, N., Urquhart, G., Morris, M., Park, J. N., & Sherman, S. G. (2020) · Health & Place · doi:10.1016/j.healthplace.2020.102376 · Cited by 33
Metadata
- Authors
- Des Jarlais, D. C.
- Venue
- Harm Reduction Journal
- Published
- 2017-07-26
- Volume
- 14
- Issue
- 1
- Pages
- 51-51
- ISSN
- 1477-7517 (ISSN-L)
- OpenAlex
- W2737600625
- Cited by
- 175
- References
- 1
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Harm reduction in the USA: the research perspective and an archive to David Purchase. https://app.cochat.ai/papers/10.1186/s12954-017-0178-6
- The paper
- Des Jarlais, D. C. (2017). Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduction Journal. https://doi.org/10.1186/s12954-017-0178-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.